ReleaseWire Connect

M Pharmaceutical Inc., (the "Company" or "M Pharma"), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has in-licensed a novel drug product that should qualify as an Orphan Drug under the US Orphan Drug Act. This new drug and its orphan status should also qualify for a Rare Pediatric Disease designation and a Priority Review Voucher (PRV). PRV's are incentives designed by the FDA to spur the development on new treatments for diseases that would otherwise not attract development interest from companies due to the cost of development and lack of market opportunities (very small patient populations). M Pharma has structured the in-license agreements by forming a private joint venture LLC with the inventor and group of private investors associated with inventor, as minority stakeholders.

M Pharmaceutical Inc, (the "Company" or "M Pharma"), announced today as part of its planned acquisition of 40 J's, that it will immediately seek marketing and distribution partnerships for the patented and proprietary topical products for the relief of menopausal symptoms that will be part of the assets being acquired. There are approximately 65 million women in North America currently nearing or experiencing menopause.

M Pharmaceutical Inc., (the "Company" or "M Pharma"), announced today as part of its planned acquisition of 40 J's, that it will immediately seek marketing and distribution partnerships for its topical products for the relief of Diabetic Neuropathy symptoms.

M Pharmaceutical Inc., (the "Company" or "M Pharma"), announced that, as part of its planned acquisition of 40 J's, it will continue to advance the development of a patented (additional patents pending) topical drug product for the treatment of female sexual dysfunction (FSD).

M Pharmaceutical Inc., (the "Company" or "M Pharma"), is announcing today that the company has executed on a Letter of Intent to acquire the assets of Cincinnati based private research and development partnership 40J's LLC (and related companies & technologies). In return for approximately 80 million shares and $1.5 million in cash to be issued or paid over the next two years, together with certain milestone payments, the Company will acquire 100% of the worldwide rights to these products and technologies. The transaction is subject to due diligence, exchange approval and other normal closing requirements for transactions of this nature.

M Pharmaceutical Inc., (the "Company" or "M Pharma"), is pleased to announce that it has engaged Camargo Pharmaceutical Services, in order to help C-103 is a novel formulation of Orlistat, patented until 2030 in the United States. Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter). Orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007. C-103 is intended to maintain the efficacy of Orlistat while minimizing its socially unacceptable side effects.

M Pharmaceutical Inc., (the "Company" or "M Pharma"), is announcing that the Company has entered into a letter of intent to acquire from ToConceive LLC., a private pharmaceutical company, the rights to an FDA approved women's health product, used as a natural conception lubricant as an infertility treatment. This acquisition is subject to further due diligence and stock exchange approval, and would see the Company issue 20 million shares and agree to pay a 5% royalty on sales.